Community post
Locus Biosciences signed a contract with CARB-X to advance a $14 million precision medicine program to develop their crPhage™ product, which targets Klebsiella pneumoniae infections.
Topics
| Source | Capsid & Tail #101 |
|---|
Locus Biosciences signed a contract with CARB-X to advance a $14 million precision medicine program to develop their crPhage™ product, which targets Klebsiella pneumoniae infections.
| Source | Capsid & Tail #101 |
|---|